Versant Ventures wraps up two funds at $700 mln
Versant Ventures has closed its seventh biotech fund at a hard cap of $600 million. Also, the healthcare investment firm closed its Canadian companion fund at $100 million. Versant Ventures Fund VII will focus on 20 or more biotech companies in the U.S., Canada and Europe while the Canadian fund, Versant Voyageurs I, will focus on five to eight startups in Canada.
17 December 2018•3 mins read
